These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
762 related articles for article (PubMed ID: 33588797)
1. Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective. Kim HS; Kang M; Kang G BMC Infect Dis; 2021 Feb; 21(1):175. PubMed ID: 33588797 [TBL] [Abstract][Full Text] [Related]
2. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia. Lee HY; Ahn J; Park J; Kang CK; Won SH; Kim DW; Park JH; Chung KH; Joh JS; Bang JH; Kang CH; Oh MD; Pyun WB; ; Korean J Intern Med; 2021 May; 36(3):617-628. PubMed ID: 33858123 [TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan. Yoshihara F; Ohtsu H; Nakai M; Tsuzuki S; Hayakawa K; Terada M; Matsunaga N; Yasuda S; Ogawa H; Ohmagari N J Cardiol; 2022 Oct; 80(4):292-297. PubMed ID: 35469713 [TBL] [Abstract][Full Text] [Related]
4. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988 [TBL] [Abstract][Full Text] [Related]
5. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19. Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367 [TBL] [Abstract][Full Text] [Related]
6. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171 [TBL] [Abstract][Full Text] [Related]
7. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients. Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528 [TBL] [Abstract][Full Text] [Related]
8. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877 [TBL] [Abstract][Full Text] [Related]
9. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. Li J; Wang X; Chen J; Zhang H; Deng A JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209 [TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality. Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317 [TBL] [Abstract][Full Text] [Related]
11. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis. Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513 [TBL] [Abstract][Full Text] [Related]
12. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911 [TBL] [Abstract][Full Text] [Related]
13. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273 [TBL] [Abstract][Full Text] [Related]
14. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202 [TBL] [Abstract][Full Text] [Related]
15. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN. Mayyas F; Bataineh W; Jarab A Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537 [TBL] [Abstract][Full Text] [Related]
16. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265 [TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea. Lee J; Lee S Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928 [TBL] [Abstract][Full Text] [Related]
18. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. Lim JH; Cho JH; Jeon Y; Kim JH; Lee GY; Jeon S; Noh HW; Lee YH; Lee J; Chang HH; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Kim SW Sci Rep; 2020 Nov; 10(1):20250. PubMed ID: 33219294 [TBL] [Abstract][Full Text] [Related]
19. [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study]. Georges JL; Cochet H; Roger G; Ben Jemaa H; Soltani J; Azowa JB; Mamou R; Gilles F; Saba J; Prevot A; Pasqualini M; Monguillon V; De Tournemire M; Bertrand A; Koukabi-Fradelizi M; Beressi JP; Livarek B Ann Cardiol Angeiol (Paris); 2020 Nov; 69(5):247-254. PubMed ID: 33039120 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System. An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]